Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

NewsBreak: Astrazeneca's Diabetes Drug Farxiga Gets U.S. Approval

Published 10/21/2019, 02:17 AM
Updated 10/21/2019, 02:31 AM
© Reuters.

Investing.com -- AstraZeneca (LON:AZN) said Monday its Farxiga drug for reducing the risk of heart failure in type-2 diabetes patients had been approved for use in the U.S. by the Food and Drug Administration.

The drug is the first inhibitor of its type to be authorized in the world's largest health market, BioPharmaceuticals Business Unit head Ruud Dobber said in a press release. There are an estimated 30 million people living with type-2 diabetes in the US, and heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke.

AstraZeneca shares are up 15% so far this year

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.